Related posts
This Week’s Stock Picks & BNN Top Picks Summary: UBER-N, C-N and 23 Stock Top Picks (Dec 13-19)Weekly 52-Week Low (or 52-Week High): K-T, CM-T, BCE-T, IPO-T and More 52-Week Highs and Lows (Dec 11-17)Monday slumpThis summary was created by AI, based on 9 opinions in the last 12 months.
Experts are generally positive about Loblaw Companies Ltd (L-T) and its future growth prospects. The company is benefitting from the softening Canadian economy as more shoppers spend at their discount banners. They have also expanded their margins and are guiding higher. The acquisition of Shoppers Drug Mart has provided a significant platform for growth, allowing them to move into healthcare. However, some caution is advised as the stock has seen a significant run-up and a pullback is expected. Overall, Loblaw Companies Ltd is seen as a strong long-term hold, with potential for further expansion and market share growth.
Loves the grocery sector, an oligopoly. Better growth prospects, better margins, but higher valuation in the space.
For consumer staples, he likes to stay close to home. Very few competitors. Stock's done very well for him.
Great year. Shopper's has been really strong, and selling/prescribing GLP-1 drugs hasn't hurt either. Likes it, though it's run up a bunch.
Continues to execute on market share and growth. More challenging recently, might be due to market rotation over to small caps. Longer-term great hold, just hold on. If you're a short-term trader, consider taking gains and rolling into something else.
Over the last decade, has evolved magnificently into a very different business. Vertically integrated. Purchase of Shoppers has been massive platform for growth. Grocery, pharmacy, and now moving into healthcare. Rich, wait for a pullback. If you own it, hold, don't sell.
Owns Shoppers, and that's one of the reasons he likes it so much. The business is being transformed all over NA, because after Covid they found it was so much cheaper to send you to get a vaccine at a pharmacy than to go to a hospital.
Remarkable sprint for a grocer and drugstore, executing well on both. Benefited from discount banners. Higher margins on strong private label portfolio. SDM is doing very well, same-store sales going up, pharmacies expanding scope of service -- increases revenue and foot traffic. Wait for a pullback to enter.
Good run, don't add new capital, not as cheap as it was. Perhaps sell calls. Name still works. 15x 2025 earnings, 10% EPS growth, healthy general margin expansion. Strong Shopper's numbers last quarter. Still likes it longer term.
Defensive consumer staple going into economic slowdown. Over half of food banners are in discount, seeing increased traffic. Plus, more people are cooking at home rather than eating out. SDM has great locations, offers Loblaw products; pharmacists expanding roles, and this increases general traffic. Yield is 1.45%.
(Analysts’ price target is $135.40)The chart is consolidating, but has been sideways for the last two years. A trade, with support around $115 to resistance around $121. Historically, this stock rises, consolidates for a while, then breaks out.
It's not their fault that food prices are so high. The bread-fixing scandal didn't help their PR. With long lines at food banks, people need a scapegoat. He owns ATD instead. This sector will remain unpopular even if it makes money.
Very few competitors, and those types of names tend to perform well long-term. Largest grocery retailer, so procures good prices and controls distribution. Shoppers Drug Mart provide lots of earnings. Loyalty programs doing well. As a consumer staple, won't participate with more cyclical names. Defensive part of your portfolio. If you're up nicely, you could take some profits.
Likes it. It's an inflation story. Some consumers are gravitating away from restaurants and back to buying their own food, so it's a volume story too. Good place to be. Trading at a reasonable 15x earnings, not overly expensive. If you think we're getting into a mild recession, which might be prolonged, this is a safe bet.
It has grown its profits very well despite modest revenue growth. It will be challenging for it maintain these high profits over the next couple of years. He is not buying since the near term growth is low.
Loblaw Companies Ltd is a Canadian stock, trading under the symbol L-T on the Toronto Stock Exchange (L-CT). It is usually referred to as TSX:L or L-T
In the last year, 9 stock analysts published opinions about L-T. 4 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Loblaw Companies Ltd.
Loblaw Companies Ltd was recommended as a Top Pick by on . Read the latest stock experts ratings for Loblaw Companies Ltd.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
9 stock analysts on Stockchase covered Loblaw Companies Ltd In the last year. It is a trending stock that is worth watching.
On 2024-12-20, Loblaw Companies Ltd (L-T) stock closed at a price of $190.62.
Wait for a pullback, given current highs. As Canada's economy softens, more shoppers spend at their discount banners. Shoppers are doing very well in beauty goods as they get out of the low-margin electronics; many provinces are allowing pharmacists to expand their role, which is another tailwind for Shoppers Drug Mart (that Loblaw owns). They are expanding their margins and guiding higher.